218 related articles for article (PubMed ID: 22741942)
1. Enteric-coated mycophenolate sodium as a steroid-sparing agent in pemphigus treatment: a retrospective study.
De Simone C; Caldarola G; Perino F; Venier A; Guerriero G
Dermatol Ther; 2012; 25(2):219-22. PubMed ID: 22741942
[TBL] [Abstract][Full Text] [Related]
2. Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus.
Bongiorno MR; Pistone G; Doukaki S; Aricò M
Int J Dermatol; 2010 Jun; 49(6):693-9. PubMed ID: 20618478
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus.
Doukaki S; Platamone A; Alaimo R; Bongiorno MR
J Dermatolog Treat; 2015 Feb; 26(1):67-72. PubMed ID: 24521072
[TBL] [Abstract][Full Text] [Related]
4. Enteric-coated mycophenolate sodium as a corticosteroid-sparing agent for the treatment of autoimmune scleritis.
Hwang YS; Chen HC; Chen KJ; Lai CC; Yeung L; Yang KJ; Lin KK; Hsiao CH
Cornea; 2011 Mar; 30(3):260-4. PubMed ID: 21099416
[TBL] [Abstract][Full Text] [Related]
5. Use of enteric coated mycophenolate sodium in adult resistant nephrotic syndrome.
Nadal MA; Lococo B; Fazzini MB; Gonzalez G; Otero AB; Malvar AV
Clin Nephrol; 2013 Jun; 79(6):439-44. PubMed ID: 23611519
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris.
Baskan EB; Yilmaz M; Tunali S; Saricaoglu H
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1432-4. PubMed ID: 19470052
[TBL] [Abstract][Full Text] [Related]
7. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil as adjuvant in pemphigus vulgaris.
Sarma N; Ghosh S
Indian J Dermatol Venereol Leprol; 2007; 73(5):348-50. PubMed ID: 17921620
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris.
Vyas N; Patel NS; Cohen GF
J Drugs Dermatol; 2013 Feb; 12(2):210-6. PubMed ID: 23377396
[TBL] [Abstract][Full Text] [Related]
10. [Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris].
Chams-Davatchi C; Nonahal Azar R; Daneshpazooh M; Valikhani M; Hallaji Z; Barzegari M; Firouz AR; Zakeri M
Ann Dermatol Venereol; 2002 Jan; 129(1 Pt 1):23-5. PubMed ID: 11937925
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).
Budde K; Knoll G; Curtis J; Chan L; Pohanka E; Gentil M; Seifu Y; Marrast AC; Neumayer HH;
Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066
[TBL] [Abstract][Full Text] [Related]
13. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent.
Esmaili N; Chams-Davatchi C; Valikhani M; Farshidfar F; Parvaneh N; Tamizifar B
Eur J Dermatol; 2008; 18(2):159-64. PubMed ID: 18424375
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
[TBL] [Abstract][Full Text] [Related]
15. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory blistering autoimmune diseases with mycophenolic acid.
Marzano AV; Dassoni F; Caputo R
J Dermatolog Treat; 2006; 17(6):370-6. PubMed ID: 17853312
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
Sollinger HW; Sundberg AK; Leverson G; Voss BJ; Pirsch JD
Transplantation; 2010 Feb; 89(4):446-51. PubMed ID: 20177347
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
19. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of enteric-coated mycophenolate sodium in patients with de novo and maintenance renal transplantation.
Qin Y; Zhang F; Shen B; Liu Y; Qiu J; Guo Y; Fan Y
Int J Clin Pract Suppl; 2014 Apr; (181):17-22. PubMed ID: 24673715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
